Featured Research

from universities, journals, and other organizations

Molecularly Targeted Drug Slows Tumor Growth In Patients

Date:
May 21, 2002
Source:
NIH/National Cancer Institute
Summary:
Researchers from the National Cancer Institute (NCI) reported today that the molecularly targeted drug bevacizumab slowed tumor growth in patients with metastatic renal cell carcinoma, the most common form of kidney cancer in adults. The findings from their randomized clinical trial were presented at the American Society for Clinical Oncology meeting in Orlando, Fla.

May 19, 2002 -- Researchers from the National Cancer Institute (NCI) reported today that the molecularly targeted drug bevacizumab slowed tumor growth in patients with metastatic renal cell carcinoma, the most common form of kidney cancer in adults. The findings from their randomized clinical trial were presented at the American Society for Clinical Oncology meeting in Orlando, Fla.

Tumor growth slowed considerably in trial patients who were given a high dose of bevacizumab. The time it took for the cancer to show measurable growth was two and a half times longer in these patients compared to those who did not receive the drug (approximately five vs. two months). Although the difference was small, it was highly statistically significant. There was also a smaller, but still significant, effect from the lower dose of bevacizumab.

Kidney cancer is diagnosed in more than 30,000 people each year in the United States. In this phase II trial, 116 patients with advanced cancer and no known effective treatment options were randomly selected to receive placebo (no drug), a low dose of the drug (3 mg/kg), or a high dose (10 mg/kg). Because only minimal side effects were associated with the drug, researchers were able to design a double-blind trial, in which neither patients nor physicians knew which treatment was being given. This rigorous trial design greatly reduces biased results.

Like other molecularly targeted drugs, bevacizumab is designed to specifically interfere with a biological process that promotes tumor growth or survival. This drug targets the angiogenic process -- the growth of new blood vessels that provide a supply of oxygen and nutrients that are necessary for a growing tumor. Bevacizumab is an antibody that neutralizes the vascular endothelial growth factor (VEGF) protein, one of many proteins secreted by tumor cells to promote the development of a new network of blood vessels. By binding to VEGF, bevacizumab prevents it from triggering blood vessel growth, thereby inhibiting tumor growth.

"The results of this trial are encouraging, demonstrating that anti-angiogenic drugs can inhibit tumor growth in patients," said James C. Yang, M.D., of NCI's Center for Cancer Research, the lead investigator on the study. "This is an important first step toward validating, in patients with cancer, the exciting advances in angiogenesis we have seen in the laboratory. We must continue to build on this finding in order to meaningfully prolong the lives of patients with advanced cancer."

More than 20 additional clinical trials are currently underway to evaluate bevacizumab as a treatment for various types of cancer. The drug is being tested in phase III trials for breast and colorectal cancer. Phase II trials with bevacizumab include those for prostate, breast, colorectal, cervical, ovarian, pancreatic, and lung cancers, as well as for mesothelioma and several types of leukemia.

For more information about cancer, please visit NCI's Web site at http://www.cancer.gov.


Story Source:

The above story is based on materials provided by NIH/National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Cancer Institute. "Molecularly Targeted Drug Slows Tumor Growth In Patients." ScienceDaily. ScienceDaily, 21 May 2002. <www.sciencedaily.com/releases/2002/05/020520074706.htm>.
NIH/National Cancer Institute. (2002, May 21). Molecularly Targeted Drug Slows Tumor Growth In Patients. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2002/05/020520074706.htm
NIH/National Cancer Institute. "Molecularly Targeted Drug Slows Tumor Growth In Patients." ScienceDaily. www.sciencedaily.com/releases/2002/05/020520074706.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins